Jump to content

Blog: Researchers Make New Inroads for EGFR Exon20+ NSCLC Patients


Recommended Posts

While our bodies can have a wide range of naturally occurring, harmless mutations in different genes, driver mutations are key to driving the development of cancer.

There are many driver mutations. Researchers have been developing drugs that target specific driver mutations in lung cancer, creating therapies for those patients whose lung cancer harbors them.

Read our latest blog where Dr. John Heymach, MD Anderson Cancer Center and member of LUNGevity’s Scientific Advisory Board, dissucses making personalized medicine even more personal.


EGFR Blog.jpg

Link to comment
Share on other sites

Join the conversation

You can post now and register later. If you have an account, sign in now to post with your account.

Reply to this topic...

×   Pasted as rich text.   Restore formatting

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

  • Create New...

Important Information

By using this site, you agree to our Terms of Use. We have placed cookies on your device to help make this website better. You can adjust your cookie settings, otherwise we'll assume you're okay to continue.